Genetic Variants of Annexin A2 and Cryptogenic Stroke
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: blood withdrawal.
- Who it may be relevant to
- Registry conditions: Annexin A2, Stroke, Genetic Variants of Host, Fibrinolysis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke. ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease. Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.
Interventions
- Biological blood withdrawal
blood withdrawal
Primary outcome measures
- genetic variants of ANXA2 [Time frame: day 1]
- genetic variants of S100A10 [Time frame: day 1]
Secondary outcome measures (4)
- blood ANXA2 concentration [Time frame: day 1]
- blood S100A10 concentration [Time frame: day 1]
- concentration of Autoantibodies directed against ANXA2 [Time frame: day 1]
- concentration of S100A10 directed against ANXA2 [Time frame: day 1]
Eligibility criteria
Inclusion criteria
- Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
- Age from 18 years old
Exclusion criteria
- Transient ischemic attack
- Pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Screening
Study locations
France · 1 center
- CHRU Amiens — Amiens
Identifiers
NCT: NCT06880107 · PI2023_843_0150